Shares are up 38.5% since reporting last quarter. Phone Number 626-350-0537 Fulgent Therapeutics was issued its CLIA license (CLIA 05D2043189/CLF 00342581). Fulgent Genetics, Inc. (NASDAQ:FLGT)’s Major holders Insiders own 46.12% of the company shares, while shares held by institutions stand at 33.14% with a share float percentage of 61.51%. Fulgent Genetics, Inc. (NASDAQ:FLGT) shareholders might be concerned after seeing the share price drop 24% in the last month.But over three years the performance has been really wonderful. --Fulgent Genetics, Inc., a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new … See here for a complete list of exchanges and delays. can be reached at his practice location using the following numbers: Phone: 626-350-0537 Check your county’s COVID-19 website.. Types of tests. TEMPLE CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (“NGS”) solutions, today announced financial results for its first quarter of fiscal year 2020 ended March 31, 2020. Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform TEMPLE CITY, Calif., Sept. 09, … FLGT has been the subject of a number of research reports. See insights on Fulgent Genetics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Another 2 recommended that FLGT is a HOLD, while 0 rated it UNDERWEIGHT and the same number … The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the company’s future performance, and they are based on management’s current assumptions, expectations and beliefs concerning future developments and their potential effect on the company’s business. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. Equities research analysts expect that Fulgent Genetics, Inc. will post 4.08 EPS for the current year. Fulgent Genetics, Inc. is a technology company. Adjusted EBITDA loss was $506,000 in the first quarter of 2020, compared to $712,000 in the first quarter of 2019. Hereditary Cancer Focus Cancer Comprehensive Cancer. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. 4978 Santa Anita Ave. Temple City, CA 91780 (US) CONTACT These reports contain more information about the company, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this press release. FULGENT GENETIC number of employees from 2015 to 2020. A diagnostic test can show if you have an active coronavirus infection. GAAP loss for the first quarter of 2020 was $2.0 million, or $0.09 per share, and non-GAAP loss was $749,000, or $0.03 per share. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for our genetic tests;  the market potential for, and the rate and degree of market adoption of, the company’s tests, including the newly-developed tests for COVID-19 and genetic testing generally; the company’s ability to capture a sizable share of the developing market for genetic testing and compete successfully in this market, including its ability to continue to develop new tests that are attractive to its various customer markets and otherwise keep pace with rapidly changing technology; the company’s ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the company’s ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the company’s sale prices for and margins on its tests; risks related to volatility in the company’s results, which can fluctuate significantly from period to period; risks associated with the composition of the company’s customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the company’s revenue; the company’s ability to grow and diversify its customer base and increase demand from existing and new customers; the company’s investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the company’s business and performance and enable it to manage any growth it may experience in future periods; the company’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the company’s level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the company’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the company’s international operations; the company’s ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. Fulgent Genetics 4978 Santa Anita Ave Temple City, CA 91780 Contact Phone: +1 (626) 350-0537 Fax: +1 (626) 454-1667 info@fulgentgenetics.com Miami-Dade County has transitioned to using Fulgent Genetics … Fulgent Genetics defines adjusted EBITDA as GAAP income (loss) plus or minus interest expense (income), plus or minus provisions (benefits) for income taxes, plus depreciation, plus equity-based compensation expenses, plus or minus equity income (loss) in investee, and plus or minus other charges or gains, as identified, that management believes are not representative of the company’s core operations. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. On November 23, 2020, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing updated revenue guidance for the 2020 fiscal year.A copy of the Company’s press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Quote and financial data from Refinitiv. Two types of COVID-19 tests are available: Diagnostic tests and antibody tests. Fulgent Genetics had a return on equity of 43.81% and a net margin of 35.31%. ADDRESS Fulgent Pharma LLC. Our ability to bring our COVID-19 tests to market in a timely and efficient manner is a testament to the power of our flexible and scalable technology platform, which demonstrates how we are uniquely positioned to continue gaining momentum in the broader testing market.”, Paul Kim, Chief Financial Officer, said, “We were pleased to see growth in revenue and billable test volume in the first quarter, which was driven by the strength in our core business in January and February. All rights reserved. Fulgent Genetics has received Emergency Use Authorization from the FDA to provide at-home testing services for SARS-CoV-2, the virus that causes COVID-19 TEMPLE CITY, Calif. , June 16, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider Jian Xie, COO, executed a sale of 7,000 shares of Fulgent Genetics (FLGT) on Nov 20, 2020, for $306,980. Fulgent Genetics, Inc. is a technology company. Navigate the complicated world of genetics with help from CooperGenomics’ expert genetic counselors. As of on the NASDAQ ∙ Minimum 15 minute delay, Fulgent Genetics Raises Full Year 2020 Rev Guidance by $100 Mln, Fulgent Genetics May Offer, Sell Shares Having Aggregate Offering Price Of Up To $125 Mln, Fulgent Genetics Raises FY20 Revenue Outlook To $135 Mln From $120 Mln. Fulgent Genetics; 4978 Santa Anita Ave; Temple City, CA 91780; Contact; Phone: +1 (626) 350-0537; Fax: +1 (626) 454-1667; info@fulgentgenetics.com The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 8333715. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events. FULGENT GENETIC number of employees from 2015 to 2020. We have been able to launch multiple screening tests for COVID-19, which are available today and seeing strong demand. 205 TEMPLE CITY, CA 91780-3600, US FULGENT THERAPEUTICS, LLC. Phone: (760) 365-9305. Fulgent Genetics, Inc. was founded in … EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. Erythrocytosis NGS Panel. Fulgent Genetics, FLGT; Department: Clinical Diagnostics Lab; 4978 Santa Anita Ave., Suite 205; Temple City, California, United States 91780; Phone: 626-350-0537 We also made significant investments across our business during the quarter, that are directly attributable to the research, development and launch efforts for our COVID-19 tests. Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from … Examples of forward-looking statements in this press release include statements about, among other things: anticipated growth of and increased stability in the company’s business and performance, including its volume and expected volume growth of billable tests delivered, and evaluations and judgments regarding diversification, traction, momentum, partnerships, and the company’s recent performance; the success of the company’s investments in its business; the timing, commercial success and impact on the company’s results of new product launches and other initiatives; and the company’s identification and evaluation of opportunities and its ability to capitalize on opportunities to grow its business. TEMPLE CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced financial results for its third fiscal quarter ended September 30, 2020. Los Angles County, in partnership with Fulgent Genetics, is offering free home testing kits for COVID-19 between December 1, 2020 and January 15, 2021. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc, (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. Press and industry analysts are invited to attend in listen-only mode. Fund performance data provided by Lipper. Fulgent Genetics is a technology company offering comprehensive genetic testing providing physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. ABOUT FULGENT:Fulgent is a leader in genetic and genomic clinical testing, a publicly traded…See this and similar jobs on LinkedIn. The company’s reports filed with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the company’s website upon their filing with the Securities and Exchange Commission. Fulgent Genetics, Inc. is a technology company.